Mohamed Yasmin T, Naguib Ibrahim A, Abo-Saif Ali A, Mohamed Wafaa R
Department of Pharmacology and Toxicology, Faculty of Pharmacy, Nahda University, Beni-Suef, Egypt.
Department of Pharmaceutical Chemistry, College of Pharmacy, Taif University, Taif, Saudi Arabia.
Drug Chem Toxicol. 2022 Nov;45(6):2509-2518. doi: 10.1080/01480545.2021.1962672. Epub 2021 Aug 13.
Indomethacin is a widely used nonsteroidal anti-inflammatory drug; however, its clinical utility is accompanied by serious adverse reactions including peptic ulcers. The current study aims to investigate the protective potential of perindopril against indomethacin-induced gastric injury in rats. Perindopril (4 mg/kg) was administered orally for 7 days and indomethacin (60 mg/kg, single oral dose) was administered on the 7 day, 1 h after perindopril administration. Pantoprazole was used as a standard agent. Ulcer index (UI), preventive index ratio (PI), histopathological examination, oxidative stress, and inflammatory biomarkers were investigated. Perindopril significantly decreased UI while increased PI and counteracted histopathological aberrations induced by indomethacin. It alleviated indomethacin-induced oxidative stress by lowering NO while increasing GSH content and superoxide dismutase activity. Perindopril significantly downregulated TNF-α and asymmetric dimethylarginine (ADMA), while significantly upregulated COX-2, PGE-2, dimethylarginine dimethylaminohydrolase-1 (DDAH-1), ANG-(1-7), and ACE-2 expression. Together, these findings suggest the gastroprotective effects of perindopril through modulation of DDAH-1/ADMA and ACE-2/ANG-(1-7) signaling.HIGHLIGHTSPerindopril attenuated gastric histopathological damage.It increased GSH content and SOD activity while decreased NO content.It modulated gastric ADMA and DDAH-1 activity.It reduced TNF-α, while increased COX-2 and PGE-2 expression.It upregulated ACE-2 activity and ANG-(1-7) protein expression.
吲哚美辛是一种广泛使用的非甾体抗炎药;然而,其临床应用伴随着包括消化性溃疡在内的严重不良反应。本研究旨在探讨培哚普利对吲哚美辛诱导的大鼠胃损伤的保护潜力。培哚普利(4mg/kg)口服给药7天,吲哚美辛(60mg/kg,单次口服剂量)在培哚普利给药后7天、1小时给予。泮托拉唑用作标准药物。研究了溃疡指数(UI)、预防指数比(PI)、组织病理学检查、氧化应激和炎症生物标志物。培哚普利显著降低UI,同时提高PI,并抵消吲哚美辛诱导的组织病理学异常。它通过降低NO含量、增加谷胱甘肽(GSH)含量和超氧化物歧化酶(SOD)活性来减轻吲哚美辛诱导的氧化应激。培哚普利显著下调肿瘤坏死因子-α(TNF-α)和不对称二甲基精氨酸(ADMA),同时显著上调环氧合酶-2(COX-2)、前列腺素E2(PGE-2)、二甲基精氨酸二甲胺水解酶-1(DDAH-1)、血管紧张素(1-7)[ANG-(1-7)]和血管紧张素转换酶2(ACE-2)的表达。总之,这些发现表明培哚普利通过调节DDAH-1/ADMA和ACE-2/ANG-(1-7)信号通路具有胃保护作用。 重点 培哚普利减轻胃组织病理学损伤。 它增加GSH含量和SOD活性,同时降低NO含量。 它调节胃ADMA和DDAH-1活性。 它降低TNF-α,同时增加COX-2和PGE-2表达。 它上调ACE-2活性和ANG-(1-7)蛋白表达。
Can J Physiol Pharmacol. 2008-3
Naunyn Schmiedebergs Arch Pharmacol. 2005-7
Naunyn Schmiedebergs Arch Pharmacol. 2024-11
Evid Based Complement Alternat Med. 2022-6-28